Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Kymanox Announces First Kymanox Executive Advisor: Fran DeGrazio

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Kymanox Corporation (“Kymanox”), a professional services provider exclusively serving the Life Science industry, is honored to announce Fran DeGrazio to the newly formed Kymanox Executive Advisors team. This team of highly distinguished industry executives has led some of the top companies in the biopharma industry, and its members are highly recognized as industry experts.

DeGrazio has over 35 years of experience in technical product development, quality, regulatory, marketing, and business strategy, serving most recently as the Chief Scientific Officer at West Pharmaceutical Services. As an industry leader, she has provided significant expertise in several areas including, but not limited to, the following:

Combination product (e.g., biologic + device) development,

Quality and regulatory strategy,

Primary packaging with special formulations for sensitive biologics, including closures for cryogenic storage used in cell and gene therapies, and

Expertise in industry-leading wearable injector platforms.

Fran DeGrazio is a frequent presenter and organizer at industry-leading conferences including the Parenteral Drug Association (PDA) and the former Xavier Health Combinations Summit. Fran DeGrazio recently received the Edward Smith Packaging Science Award at the 2022 PDA Annual Meeting in Dallas for outstanding lifetime contributions in packaging for the pharmaceutical industry.

Michael Denzer, a key executive at Kymanox, states, “Our mission is to help the industry deliver critical medicines to humanity – quickly and reliably. Fran brings an incredible wealth of knowledge, expertise, experience, and passion for medicinal product development. Fran’s guidance will help Kymanox double-down on our mission and assist our clients to speed their Combination Products, including Cell & Gene Therapies, to market.”

“Fran DeGrazio, as our first Kymanox Executive Advisor (KEA), will solidify our strategic professional advisement services and further establish Kymanox as an industry thought leader,” said Stephen M. Perry, CEO and Founder at Kymanox. “Fran is the perfect person to be bestowed the honor as our first KEA member; we look forward to adding to the team in the coming weeks and continuing to advise organizations on their most challenging strategy opportunities.”

Fran DeGrazio holds a degree in Chemistry from Cabrini University. She is active in PDA and serves on several industry committees throughout the year.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine